Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-08-13 6:53 pm Purchase | 13D | Design Therapeutics Inc. DSGN | Logos Global Management LP | 4,232,627 7.500% | 1,420,126 (+50.49%) | View |
| 2024-02-14 4:58 pm Sale | 13G | Design Therapeutics Inc. DSGN | CITADEL ADVISORS LLC | 1,834,854 3.300% | -1,036,413 (-36.10%) | View |
| 2024-02-14 3:01 pm Sale | 13G | Design Therapeutics Inc. DSGN | Cormorant Asset Management LP | 0 0.000% | -5,150,000 (Position Closed) | View |
| 2024-01-23 10:34 am Sale | 13G | Design Therapeutics Inc. DSGN | STATE STREET CORP STT | 695,224 1.240% | -2,342,236 (-77.11%) | View |
| 2023-11-14 5:00 pm Sale | 13G | Design Therapeutics Inc. DSGN | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -2,971,231 (Position Closed) | View |
| 2023-09-07 09:38 am Sale | 13G | Design Therapeutics Inc. DSGN | BlackRock Inc. BLK | 2,394,544 4.300% | -1,113,480 (-31.74%) | View |
| 2023-04-03 4:55 pm Purchase | 13G | Design Therapeutics Inc. DSGN | CITADEL ADVISORS LLC | 2,871,267 5.100% | 203,037 (+7.61%) | View |
| 2023-02-14 3:14 pm Sale | 13G | Design Therapeutics Inc. DSGN | Cormorant Asset Management LP | 5,150,000 9.210% | -290,451 (-5.34%) | View |
| 2023-02-14 08:14 am Sale | 13G | Design Therapeutics Inc. DSGN | CITADEL ADVISORS LLC | 2,668,230 4.800% | -40,017 (-1.48%) | View |
| 2023-02-08 1:03 pm Purchase | 13G | Design Therapeutics Inc. DSGN | STATE STREET CORP STT | 3,037,460 5.430% | 3,037,460 (New Position) | View |
| 2023-02-03 12:10 pm Purchase | 13G | Design Therapeutics Inc. DSGN | BlackRock Inc. BLK | 3,508,024 6.300% | 3,508,024 (New Position) | View |
| 2022-12-22 4:25 pm Purchase | 13D | Design Therapeutics Inc. DSGN | SR One Capital Fund I Aggregator LP | 6,550,226 11.710% | 908,750 (+16.11%) | View |
| 2022-12-22 4:01 pm Purchase | 13G | Design Therapeutics Inc. DSGN | CITADEL ADVISORS LLC | 2,708,247 4.800% | 2,708,247 (New Position) | View |
| 2022-10-13 4:30 pm Purchase | 13G | Design Therapeutics Inc. DSGN | RA CAPITAL MANAGEMENT L.P. | 2,971,231 5.320% | 2,971,231 (New Position) | View |
| 2022-03-31 4:23 pm Purchase | 13D | Design Therapeutics Inc. DSGN | Logos Global Management LP | 2,812,501 5.000% | 2,812,501 (New Position) | View |
| 2022-02-14 3:08 pm Purchase | 13G | Design Therapeutics Inc. DSGN | Cormorant Asset Management LP | 5,440,451 9.770% | 325,607 (+6.37%) | View |
| 2022-02-09 4:32 pm Purchase | 13G | Design Therapeutics Inc. DSGN | Ansari Aseem Z. | 7,668,711 13.800% | 7,668,711 (New Position) | View |
| 2022-02-09 4:30 pm Purchase | 13G | Design Therapeutics Inc. DSGN | Light Irrevocable Trust #1 dated April 22 2019 | 3,834,355 6.900% | 3,834,355 (New Position) | View |
| 2022-02-09 4:25 pm Purchase | 13G | Design Therapeutics Inc. DSGN | Star Irrevocable Trust #1 dated April 22 2019 | 3,834,355 6.900% | 3,834,355 (New Position) | View |
| 2021-04-09 4:07 pm Purchase | 13G | Design Therapeutics Inc. DSGN | Cormorant Asset Management LP | 5,114,844 9.200% | 5,114,844 (New Position) | View |